KRYS - Krystal Biotech

-

$undefined

N/A

(N/A)

Krystal Biotech NasdaqGS:KRYS Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Location: 2100 Wharton Street, Pittsburgh, PA, 15203, United States | Website: https://www.krystalbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

3.023B

Cash

616.8M

Avg Qtr Burn

N/A

Short % of Float

11.40%

Insider Ownership

12.21%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
VYJUVEKTM (B-VEC) (Topical Beremagene Geperpavec) Details
Skin disease/disorder, Dystrophic epidermolysis bullosa, Epidermolysis bullosa

Approved

Quarterly sales

KB803 (Ophthalmic B-VEC) Details
Dystrophic epidermolysis bullosa

Phase 3

Initiation

Phase 2

Initiation

KB105 Details
Skin disease/disorder, TGM1-deficient lamellar ichthyosis

Phase 1/2

Initiation

KB707 (IL-2 and IL-12) Details
Solid tumor/s, Multiple tumors, Cancer

Phase 1

Data readout

Phase 1

Data readout

KB408 Details
Severe alpha-1 antitrypsin deficiency

Phase 1

Data readout

KB407 Details
Cystic fibrosis

Phase 1

Data readout

Inhaled KB707 Details
Solid tumor/s, Lung Metastases, Cancer

Phase 1

Data readout